Ropes & Gray has advised Eli Lilly and Company. Latham & Watkins has advised AtaiBeckley Inc. Eli Lilly and Company (NYSE: LLY) has entered into a...
Eli Lilly Acquires AtaiBeckley to Expand Mental Health Treatment Pipeline in $3.8 Billion Deal
Thermo Fisher to Sell Microbiology Business to Astorg for $1.075 Billion
Cravath, Swaine & Moore LLP, Axinn, Veltrop & Harkrider LLP, Hogan Lovells, and Perella Weinberg Partners and Wells Fargo have advised Thermo Fisher Scientific. Latham &...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
IDEAYA Biosciences’ $175 Million Common Stock Public Offering
Latham & Watkins represents IDEAYA Biosciences in the offering. IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the pricing of an underwritten public offering of common stock and...
Revolution Medicines’ $345 Million Common Stock Public Offering
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
Bausch + Lomb’s Acquisition of AcuFocus
Latham & Watkins LLP represented AcuFocus in the transaction. Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see...
Indivior’s $145 Million Acquisition of Opiant Pharmaceuticals
Covington & Burling LLP advised Indivior, while Latham & Watkins LLP represented Opiant in the transaction. Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) has entered into a definitive...
IDEAYA Biosciences’ $80 Million Common Stock Offering
Latham & Watkins represented IDEAYA, while Davis Polk advised the representatives of the several underwriters in the offering. IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced the pricing of an...
Revolution Medicines’ $230 Million Shares Offering
Latham & Watkins represented Revolution Medicines, while Davis Polk advised the underwriters in the offering. Revolution Medicines, Inc. (Nasdaq: RVMD), has announced the pricing of its underwritten...
SmileDirectClub’s $255 Million Debt Facility
Latham & Watkins represented the lender, HPS Investment Partners, in the transaction. SDC US SmilePay SPV’s (SPV), a wholly-owned special purpose subsidiary of SmileDirectClub, Inc. announced...
Aligos Therapeutics’ $83.6 Million Public Offering
Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced...
Angion Biomedica’s Initial Public Offering and Concurrent Private Placement
Latham & Watkins LLP represented Angion in the offering and private placement. Angion Biomedica Corp. (NASDAQ:ANGN) has announced the pricing of its initial public offering of 5...